title: Blinatumomab (Blincyto): lessons learned from the bispecific t-cell engager (BiTE) in acute lymphocytic leukemia (ALL).
authors.affiliation: Translational Sciences, Amgen, Inc, Thousand Oaks, California, USA.
authors.forename: G
authors.initials: G
authors.lastname: Friberg
authors.affiliation: Translational Sciences, Amgen, Inc, Thousand Oaks, California, USA.
authors.forename: D
authors.initials: D
authors.lastname: Reese
mesh_terms: D018033:Antibodies, Bispecific / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002986:Clinical Trials as Topic; D006801:Humans; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000276:immunology*; D013601:T-Lymphocytes / Q000187:drug effects* / Q000276:immunology
chemical_list: D018033:Antibodies, Bispecific; D000970:Antineoplastic Agents; C510808:blinatumomab